Registry of Multicenter Brain-Heart Comorbidity in China

This study is a multi-center, prospective, registry study. This research was supported by the National Key Research and Development Program. To establish a domestic multi-center, large-scale "brain-heart comorbidity" dynamic database platform including clinical, sample database, image and other multi-dimensional information requirements, through the construction of a multi-center intelligent scientific research integration platform based on artificial intelligence.

Any of newly diagnosed cardiovascular related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) [i.e., ACS], I46 (cardiac arrest), I48 (Atrial fibrillation/flutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).

The data is stored on the brain-heart comorbidity warehouse via a physical server at the institution's data centre or a virtual hosted appliance. The brain-heart comorbidity platform comprises of a series of these appliances connected into a multicenter network. This network can broadcast queries to each appliance. Results are subsequently collected and aggregated. Once the data is sent to the network, it is mapped to a standard and controlled set of clinical terminologies and undergoes a data quality assessment including 'data cleaning' that rejects records which do not meet the brain-heart comorbidity quality standards. The brain-heart comorbidity warehouse performs internal and extensive data quality assessment with every refresh based on conformance, completeness, and plausibility (http://10.100.101.65:30080/login).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ischemic Heart Disease Aneurysm Aortic Diseases Arrhythmias, Cardiac Arterial Occlusive Diseases Arteriovenous Malformation of Cerebral Vessels Arteriovenous Malformations Atrial Fibrillation Bites and Stings Brain Diseases Brain Infarction Brain Ischemia Cardiac Arrest Cardiovascular Abnormalities Cardiovascular Diseases Carotid Artery Diseases Central Nervous System Diseases Central Nervous System Vascular Malformations Cerebral Aneurysm Cerebral Arterial Diseases Cerebral Hemorrhage Cerebral Infarction Cerebrovascular Disorders Chemically-Induced Disorders Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Heart Arrest Heart Diseases Heart Failure Hemorrhage Infarction Intracerebral Hemorrhage Intracranial Aneurysm Intracranial Arterial Diseases Intracranial Arteriovenous Malformations Intracranial Hemorrhages Ischemia Moyamoya Disease Myocardial Ischemia Necrosis Nervous System Diseases Nervous System Malformations Occlusion and Stenosis of Cerebellar Arteries Occlusion and Stenosis of Precerebral Arteries Pathologic Processes Pathological Conditions, Signs and Symptoms Poisoning Stroke Subarachnoid Hemorrhage Vascular Diseases Vascular Malformations Wounds and Injuries

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing Municipality, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age > 18 years old
Any of newly diagnosed cardiovascular-related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) [i.e., ACS], I46 (cardiac arrest), I48 (Atrial fibrillation/flutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).

Exclusion criteria

·refuse to participate in the registry

Treatment and study plan

Multi-disciplinary assessment

Other

Multi-disciplinary assessment

Primary outcomes

Rate of Participants with Composite of All-Cause Mortality and Cardiovascular Outcomes

Time frame: At discharge/30 days

The occurrence of all-cause mortality, coronary artery disease event, stroke (ischemic or hemorrhagic), heart failure, or atrial fibrillation etc.
All-Cause Mortality

Time frame: At discharge/30 days

The occurrence of death
Rate of Participants with Composite of Cardiovascular Outcomes

Time frame: At discharge/30 days

The occurrence of coronary artery disease event, stroke (ischemic or hemorrhagic), heart failure, or atrial fibrillation etc.

Study contacts

Contact information is provided by the study sponsor or research team.

Fa Lin, MD

CONTACT

[email protected]

13681107240

Xiaolin Chen, MD

CONTACT

[email protected]

13810624845

Sponsors and collaborators

Lead sponsor

Beijing Tiantan Hospital

Other

Registry information

Acronym: BHC-C

Important dates

Study start: 2012
Primary completion: 2032
Study completion: 2032
First posted: Jul 27, 2023
Registry last updated: Sep 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting